In a filing with the Securities and Exchange Commission Monday, Mr. Chen, who has a roughly 13.8 percent stake in CHS, said he intends to engage with Community Health Systems’ management team regarding the company’s business, operations and ongoing turnaround strategy.
The filing signals a possible change in Mr. Chen’s involvement with CHS. Last October, Shanda Group, a Singapore-based investment firm owned by Mr. Chen, released a statement on its website indicating Mr. Chen’s wholly owned group of companies would remain passive investors in CHS, despite being the for-profit hospital operator’s largest private shareholder.
The filing comes roughly three weeks before CHS’ “poison pill” expires April 1. The poison pill, or shareholders’ rights agreement, was put in place last October to prevent a single entity from accumulating a potentially controlling block of CHS’ common stock until the for-profit operator could explore other alternatives.
More articles on healthcare finance:
13 recent hospital outlook and credit rating actions
S&P affirms ‘CCC’ rating on Verity Health System’s bonds, revises outlook to positive
Fitch assigns ‘AA’ rating to Seattle Children’s Hospital’s bonds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.